TY - JOUR
T1 - Prognostic factors in ovarian carcinosarcoma
T2 - A clinicopathological and immunohistochemical analysis of 23 cases
AU - Ariyoshi, K.
AU - Kawauchi, S.
AU - Kaku, T.
AU - Nakano, H.
AU - Tsuneyoshi, M.
PY - 2000
Y1 - 2000
N2 - Carcinosarcoma of the ovary is a rare, highly aggressive neoplasm comprising histologically of both epithelial and mesenchymal components. The aim of this study was to evaluate the clinicopathological prognostic factors in ovarian carcinosarcoma, including the immunohistochemical expression of p53 protein and Ki67. Methods and results: Twenty-three cases of carcinosarcoma of the ovary were studied retrospectively. The clinicopathological and immunohistochemical parameters including p53 and Ki67 staining were statistically analysed to investigate the prognostic significance of this tumour. The overall 5-year survival rate was 27.1%; 100% for stage I, 31.3% for stage II, 10.9% for stage III and 0% for stage IV. The low-stage group (stages I and II) was found to be a significant prognostic factor for patient survival (P = 0.0113). None of the other factors (tumour size, histological type of carcinomatous and sarcomatous components, mitotic count, vascular space invasion and immunoreactivity for p53 protein and Ki67) was found to be a statistically significant prognostic indicator. Conclusions: Ovarian carcinosarcoma is a rare malignancy with poor prognosis. In this study, advanced stage appears to be poor prognostic indicator of survival in patients with ovarian carcinosarcoma.
AB - Carcinosarcoma of the ovary is a rare, highly aggressive neoplasm comprising histologically of both epithelial and mesenchymal components. The aim of this study was to evaluate the clinicopathological prognostic factors in ovarian carcinosarcoma, including the immunohistochemical expression of p53 protein and Ki67. Methods and results: Twenty-three cases of carcinosarcoma of the ovary were studied retrospectively. The clinicopathological and immunohistochemical parameters including p53 and Ki67 staining were statistically analysed to investigate the prognostic significance of this tumour. The overall 5-year survival rate was 27.1%; 100% for stage I, 31.3% for stage II, 10.9% for stage III and 0% for stage IV. The low-stage group (stages I and II) was found to be a significant prognostic factor for patient survival (P = 0.0113). None of the other factors (tumour size, histological type of carcinomatous and sarcomatous components, mitotic count, vascular space invasion and immunoreactivity for p53 protein and Ki67) was found to be a statistically significant prognostic indicator. Conclusions: Ovarian carcinosarcoma is a rare malignancy with poor prognosis. In this study, advanced stage appears to be poor prognostic indicator of survival in patients with ovarian carcinosarcoma.
UR - http://www.scopus.com/inward/record.url?scp=0033749821&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033749821&partnerID=8YFLogxK
U2 - 10.1046/j.1365-2559.2000.01015.x
DO - 10.1046/j.1365-2559.2000.01015.x
M3 - Article
C2 - 11119124
AN - SCOPUS:0033749821
SN - 0309-0167
VL - 37
SP - 427
EP - 436
JO - Histopathology
JF - Histopathology
IS - 5
ER -